BCG Vaccine Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

BCG Vaccine Market Analysis

The Global BCG Vaccine Market size is estimated at USD 159.05 million in 2024, and is expected to reach USD 215.58 million by 2029, growing at a CAGR of 6.27% during the forecast period (2024-2029).

The COVID-19 pandemic had a substantial impact on the BCG vaccine market initially. The strict lockdowns and government regulations intended to slow down the spread of COVID-19 resulted in a decrease in demand for the BCG vaccine due to the lack of visits to healthcare facilities such as hospitals and clinics. The outbreak of the pandemic also resulted in a shortage of support staff for pediatric vaccination, which includes BCG vaccination as well. Moreover, the vaccine manufacturing companies prioritized manufacturing COVID-19 vaccines instead of other vaccines, which in turn created a shortage of BCG vaccines as well.

For instance, a modeling study was conducted to evaluate the impact of COVID-19 on global BCG vaccine coverage and was published in October 2021 in the journal of the National Center for Biotechnology Information (NCBI). The results of the study showed that there was substantial variation in the impact of COVID-19 on routine BCG vaccination programs; some African countries showed average BCG coverage, while others showed lower rates from January to June 2020. It also found that there was a 50 percent decline in BCG coverage in India during the pandemic period. Furthermore, as per an article titled 'Impact of COVID-19 on routine immunization in South-East Asia and Western Pacific: Disruptions and Solutions,' published in the journal The Lancet in April 2021, fear of infection, restriction of movement, and limited access to healthcare were the main reasons for COVID-related disruption to immunization services which includes BCG vaccination as well. Thus, the COVID-19 outbreak affected the market's growth adversely in its preliminary phase; however, the market is expected to gain traction due to the significant increase in the use of BCG vaccines globally.

Further, the rising prevalence of tuberculosis, technological advancement in vaccine research and development, and rise in government initiatives for vaccination programs are among the significant factors driving the studied market growth. Poverty, homelessness, and HIV infections are the main causes of tuberculosis and the BCG vaccine is the only vaccine that prevents infection by the mycobacterium tuberculosis bacteria.

Moreover, according to World Health Organization (WHO), 1.5 million died from tuberculosis in 2020. Tuberculosis is the 13th leading cause of death worldwide, and its also the second leading infectious disease after COVID-19. Additionally, in 2020 an estimated 10 million people fell ill due to tuberculosis worldwide its also stated that tuberculosis is present in all countries and can infect all age groups. Therefore, the rising prevalence of tuberculosis and increasing death due to it is expected to boost the BCG vaccine market globally, driving the need for BCG vaccine and thereby fueling the growth of the studied market over the forecast period.

In addition, the BCG vaccine is also used to treat patients who have bladder cancer. According to the American Cancer Society, it is the most common intravesical immunotherapy for treating early-stage bladder cancer. It is used to help keep cancer from growing and to help keep it from coming back. BCG is an inactivated germ that is used as a vaccine to prevent tuberculosis, but in the case of bladder cancer, this germ is put directly in the bladder through a catheter so that it can turn on the immune system of the patient.

Moreover, according to an article titled 'A BCG success story: From prevention of tuberculosis to optimal bladder cancer treatment,' published in the journal of the National Center for Biotechnology Information (NCBI) in August 2021, an observational study was performed to see the effect of BCG vaccine against existing bladder cancer, and it was concluded that BCG vaccine is the most effective drug for the treatment of localized bladder cancer. Thus, owing to the increasing usage of BCG vaccine for treating different diseases, the studied market is expected to have significant growth over the forecast period.

However, the side effects associated with using the BCG vaccine and shortage of supply are likely to impede market growth.

BCG Vaccine Market Trends

This section covers the major market trends shaping the BCG Vaccine Market according to our research experts:

The Pediatrics Segment Dominates the BCG Vaccine Market

BCG Vaccine Industry Segmentation

The Bacillus of Calmette-Guerin (BCG) vaccine is made from a weakened strain of tuberculosis bacteria. As the bacteria in the vaccine is weak, it triggers a person's immune system to protect them against tuberculosis, but it does not cause the infection. It provides constant protection against tuberculosis throughout the lifespan of a person. 

The BCG Vaccine Market is segmented by Age Group (Pediatrics and Adults), Application (Tuberculosis and Bladder Cancer), Distribution Channel (Hospitals, Clinics, and Other Distribution Channels), and Geography (North America, Europe, Asia-Pacific, and Rest of the World). The report offers the value (in USD million) for the above segments.